Atorvastatin restores the balance between pro-inflammatory and anti-inflammatory mediators in rats with acute myocardial infarction

European Review for Medical and Pharmacological Sciences

Volumn 14, Issue 6, 2010, Pages 499-506

  Tawfik, Mona K ^a   Ghattas, Maivel H ^a   Abo Elmatty, Dina M ^a   Abdel Aziz, Nagla A ^b  

^a SUEZ CANAL UNIVERSITY   (Egypt)

^b Suez Canal University Faculty of Medicine   (Egypt)

Author keywords

Atorvastatin; Experimental acute myocardial infarction; Interleukin 10; Plasminogen activator inhibitor 1; Tumor necrosis factor

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CREATINE KINASE; CREATINE KINASE MB; INTERLEUKIN 10; ISOPRENALINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG MECHANISM; ELECTROCARDIOGRAM; FIBRINOLYSIS; INFLAMMATION; MALE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RAT; ST SEGMENT ELEVATION; ACUTE DISEASE; ANIMAL; BLOOD; DRUG EFFECTS; ELECTROCARDIOGRAPHY; HEART INFARCTION; IMMUNOLOGY; WISTAR RAT;

ACUTE DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS; C-REACTIVE PROTEIN; ELECTROCARDIOGRAPHY; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-10; MALE; MYOCARDIAL INFARCTION; PLASMINOGEN ACTIVATOR INHIBITOR 1; PYRROLES; RATS; RATS, WISTAR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77955799411     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. STANLEY C, CHRISTOPHER A, KEITH A, DAVID E. Acute systemic inflammation enhances endothelium-dependent tissue plasminogen activator release in men. J Am Coll Cardiol 2003; 41: 333-339.
2. PAUL M, CHARLES H, JULIE E, NADER R. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843. (Pubitemid 30165206)
3. GAVIN J, PAUL M. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol 2003; 41: 37-42.
4. DAVID A, SANDRA D, JOANNA S, DELLA C, JUAN C. Serum levels of the anti-inflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation 2001; 104: 746.
5. MICHAEL R, MICHAEL S, PIER D, CLIFFORD A SIMON R. Systemic inflammation in unstable angina is the result of myocardial necrosis . J Am Coll Cardiol 2002; 39: 1917-1923.
6. TZIAKAS DM , CHALIKIAS GK, HATZINIKOLAOU HI, PARISSIS JT, PAPADOPOULOS ED, TRYPISANIS GA PAPADOPOULOS E, TENTES IK, KARAS SM, HATSERAS DI. Anti-inflammatory cytokine profiles in acute coronary syndromes: behavior of interleukins-10 in association with serum metalloproteinases and proinflammatory cytokines. Int J Cardiol 2003; 92: 169-175.
7. KOCH W, TIROCH K, BECKERATH N, SCHÓMIG A, KASTRATI A. Tumor necrosis factor-α, lymphotoxin-α, and interleukins-10 gene polymorphisms and restenosis after coronary artery stenting. Cytokine 2003; 24: 161-171. (Pubitemid 37297879)
8. EHRIN J, DAVID A, MARC S. Inflammatory biomarkers in acute coronary syndromes. Circulation. 2006; 113: e72-e75.
9. OLIVIERI F, ANTONICELLI R, CARDELLI M, MARCHEGIANI F, CAVALLONE L, MOCCHEGIANI E, FRANCESCHI C. Genetic polymorphism of inflammatory cytokines and myocardial infarction in the elderly. Mech Ageing Dev 2006; 127: 552-559.
10. DOMINGUEZ-RODRIGUEZ A, ABREU-GONZALEZ P, DE LA ROSA A, VARGAS M. FERRER J, GARCIA M. Role of endogenous interleukins-10 production and lipid peroxidation in patients with acute myocardial infarction treated with primary percutaneous transluminal coronary angioplasty interleukin-10 and primary angioplasty. Int J Cardiol 2005; 99: 77-81. (Pubitemid 40261028)
11. WAEHRE T, YNDESTAD A, SMITH C, HAUG T, TUNHEIM SH, GULLESTAD L, FRØLAND SS, SEMB AG, AUKRUST P, DAMÅS JK. Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors. Circulation 2004; 109: 1966-1972.
12. BOUNAMEAUX H, KRUITHOF EK. On the association of elevated tPA/PAI-1 complex and Von Willebrand factor with recurrent myocardial infarction. Arterioscler Thromb Vasc Biol 2000; 20: 1857-1859.
13. FRANGOGIANNIS NG, WAYNE SMITH C, ENTMAN ML. The inflammation response in myocardial infarction. Cardiovasc Res 2002; 53: 31-47.
14. STEIN M, BROWN N, VAUGHAN D E, LANG CC, WOOD AJ. Regulation of local tissue-type plasminogen activator release by endothelium-dependent and endothelium independent agonist in human vasculature. J Am Coll Cardiol 1998; 32: 117-122.
15. ALMUTI K, RIMAWI R, SPEVACK D, OSTFELD RJ. Effect of statins beyond lipid lowering: Potential for clinical benefits. Int J Cardiol 2006; 109: 7-15.
16. LIAO JK. Effects of statins on 3-hydroxy-3-methyl-glutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005; 96: 24F-33F.
17. WOLFRUM S, DENDORFER A, SCHUTT M, WEIDTMANN B, HEEP A, TEMPEL K, KLEIN HH, DOMINIAK P, RICHARDT G. Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway. J Cardiovasc Pharmacol 2004; 44: 348-355.
18. BANERJEE SK, SOOD S, DINDA AK, DAS TK, MAULIK SK. Chronic oral administration of raw garlic protects against isoproterenol-induced myocardial necrosis in rat. Comp Biochem Physiol C Toxicol Pharmacol 2003; 136: 377-386.
19. BARSANTE MM, ROFFE̊ E, YOKORO CM, TAFURI WL, SOUZA DG, PINHO V, CASTRO MS, TEIXEIRA MM. Anti-inflammatory and analgesic effects of atorvastatin in a rat model of adjuvant-induced arthritis. Eur J Pharmacol 2005; 516: 282-289.
20. IWAMOTO K, WATANABE J, ATSUMI F. Effects of urethane anesthesia and age on organ blood flow in rats measured by hydrogen gas clearance method. J Pharmacobiodyn 1987; 10: 280-284.
21. CAIRNS J, MISSIRLIS E, WALKER C. Usefulness of serial determination of myoglobin and creatine kinase in serum compared for assessment of acute myocardial infarction. Clin Chem 1983; 29: 469-473.
22. HIGHTON J, HESSIAN PA. A solid phase enzyme immunoassay for CRP: Clinical value on the effect of rheumatoid factor. J Immunol Methods 1984; 68: 182-192.
23. MY LIWSKA J, ZORENA K, BAKOWSKA A, SKURATOWICZ-KUBICA A, MY LIWSKI A. Significance of tumor necrosis factor-alpha in patients with long standing type-1 diabetes mellitus. Horm Metab Res 1998; 30: 158-161.
24. OKURA Y, TAKEDA K, HONDA S, HANAWA H, WATANABE H, KODAMA M, IZUMI T, AIZAWA Y, SEKI S, ABO T. Recombinant murine interleukin 12 facilitates induction of cardiac myosin specific type 1 helper T cells in rats. Circ Res 1998; 82: 1035-1042.
25. NGO TH, VERHEYEN S, KNOCKAERT I, DECLERCK PJ. Monoclonal antibody based immunoassay for specific quantitation of rat PAI-1 antigen and activity in biological samples. Thromb Haemost 1998; 79: 808-812.
26. DHALLA N, YATES J, NAIMARK B. Cardio toxicity of catecholamines and related agents. In: Acosta D (ed): Cardiovascular Toxicology, 2d ed. New York: Raven Press, 1992: pp. 239-282.
27. FERRARI R, CECONI C, CURELLO S, ALFIERI O, VISIOLI O. Myocardial damage during ischemia and reperfusion. Eur Heart J 1993; 14: 25-30.
28. MARJOMÄKI V, RITAMÄKI V, GRUENBERG J. Isoproterenol-induced redistribution of endosomes in cardiac myocytes. Eur J Cell Biol 1994; 65: 1-13.
29. BUJA A. Modulation of the myocardial response to ischemia. Lab Invest 1998; 78: 1345-1373.
30. CUSACK MR, MARBER MS, LAMBIASE PD, BUCKNALL CA, REDWOOD SR. Systemic inflammation in unstable angina is the result of myocardial necrosis. J Am Coll Cardiol 2002; 39: 1917-1923.
31. CHEN X, WU H, HUANG X, WU X. The alteration of inflammatory cytokine during acute pancreatitis. Hua Xi Yi Ke Da Xue Xue Bao 2002; 33: 238-240, 243.
32. STEPPICH BA, MOOG P, MATISSEK C, WISNIOWSKI N, K HLE J, JOHETAEI N, NEUMANN F-J, SCHOMIG A, OTT I. Cytokine profiles and T cell function in acute coronary syndromes. Atherosclerosis 2006; 18: 1-9.
33. SATOH M, SHIMODA Y, MAESAWA C, AKATSU T, ISHIKAWA Y, MINAMI Y, HIRAMORI K, NAKAMURA M. Activated toll-like receptor 4 in monocytes is associated with heart failure after acute myocardial infarction. Int J Cardiol 2006; 109: 226-234.
34. DAS UN. Free radicals, cytokines and nitric oxide in cardiac failure and myocardial infarction. Mol Cell Biochem 2000; 215: 145-152.
35. KRISHNASWAMY G, SMITH JK, MUKKAMALA R, HALL K, JOYNER W, YERRA L, CHI DS. Multifunctional cytokine expression by human coronary endothelium and regulation by monokines and glucocorticoids. Microvasc Res 1998; 55: 189-200.
36. LIPPY P, RIDKER PM, MASERI A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.
37. PASQUI AL, DI RENZO M, AUTERI A, PUCCETTI L. Cytokines in coronary syndromes. Int J Cardiol 2005; 105: 355-356.
38. FEI GZ, SVENUNGSSON E, FROSTEGÅRD J, PADYUKOV L. The A-1087IL-10 allele is associated with cardiovascular disease in SLE. Atherosclerosis 2004; 177: 409-414.
39. LOPEZ S, PEIRETTI F, BONARDO B, DEPREZ-BEAUCLAIR P, LAOUENAN H, JUHAN-VAGUE I, NALBONE G. Effect of atorvastatin on plasminogen activator inhibitor type-1 synthesis in human. J Cardiovasc Pharmacol 2001; 37: 762-768. (Pubitemid 32480445)
40. MUTCH NJ, WILSON HM, BOOTH NA. Plasminogen activator inhibitor-1 and haemostasis in obesity. Proc Nutr Soc 2001; 60: 341-347. (Pubitemid 32772449)
41. ANGUERA I, MIRANDA F, BOSCH X, FIELLA X, SITGES M, MARIN J, BETRIU A, SANZ G. Evaluation of serum levels of the anti-inflammatory cytokine interleukin-10 and decreased risk of coronary events in patients with unstable angina. Am Heart J 2002; 144: 811-817.
42. TOUSOULIS D, ANTONIADES C, BOSINAKOU E, KOTSOPOULOU M, TSIOUFIS C, TENTOLOURIS C, TRIKAS A, PITSAVOS C, STEFANADIS C. Effect of atorvastatin on reactive hyperaemia and thrombosis-fibrinolysis system in patient with heart system. Heart 2005; 91: 27-31.
43. BRUNI E PASQUI AL, PASTORELLI M, BOVA G, DI RENZO M, CERCIGANI M, LEO A, AUTERI A, PUCCETTI L. Effect of atorvastatin on different fibrinolysis mechanisms in hypercholesterolemic subjects. Int J Cardiol 2004; 95: 269-274.